Courtagen’s genetic tests take advantage of recent advances in the next generation sequencing technology, and enable new opportunities to elucidate genetic causes of disorders such as epilepsy, intellectual disability, autism spectrum disorders, and mitochondrial dysfunction to guide treatment to improve the patient’s quality of life.
Bioinn business development manager Paulina Chao said: " Courtagen’s cutting edge NGS platform will help local clinicians and many families suffering from a complicated neurological or metabolic disorder."
Courtagen president Brendan McKernan said that the distribution agreement with Bioinn is another important step in the execution of its global strategy to support the increasing demand of its products.
"We look forward to a successful partnership," McKernan added.
